Vivaldi Biosciences

Vivaldi Biosciences Develops Live Attenuated Influenza Vaccines to Address the Most Pressing Public Health Issues of Influenza. The company's vaccines leverage the biological properties of influenza proteins to counteract human immune responses mediated by interferons and incorporate a transgenic influenza vaccine strain that lacks activity but elicits a strong immune response, enabling patients to combat both common seasonal influenza and emerging pandemic influenza.